Background/Aims Sarcopenia is an independent prognostic factor of liver cirrhosis (LC). However, the association between LC-related systemic inflammation and sarcopenia is unclear.
Methods Sprague-Dawley rats were treated with thioacetamide (TAA) or saline as a control. Rifaximin was administered to TAA-induced LC rats. Enzyme-linked immunosorbent assay was performed to measure inflammatory mediators in rat serum. RT-PCR was performed to measure the molecular expression in tissues. Hematoxylin and eosin (H&E) staining and immunohistochemistry were performed to investigate tissue pathology. Serum tumor necrosis factor-α levels, liver stiffness (LS), and the L3 skeletal muscle index (L3SMI) were measured in 60 patients with chronic liver disease.
Results LC and sarcopenia were successfully induced by TAA. Serum TNF-α levels were increased in LC rats and correlated with myostatin expression, muscle weight, and myofiber diameter. The expression of intestinal occludin and zona occludens-1 was reduced in LC rats and associated with serum TNF-α levels and sarcopenia. In patients with LS ≥7 kPa or sarcopenia, serum TNF-α levels were significantly increased, which was also confirmed when we raised the LS cutoff to 10 kPa. The L3SMI was inversely correlated with serum TNF-α levels in patients with LS ≥7 kPa. TNF-α was reduced by rifaximin, which might have resulted in reduced expression of muscular MuRF1 and myostatin and improvements in myofiber diameters within muscle tissues.
Conclusions These results suggest that serum TNF-α is associated with LC-related sarcopenia. Rifaximin might be effective in reducing serum TNF-α levels and improving sarcopenia in LC, but these results need to be validated in future studies.
Citations
Citations to this article as recorded by
New nomenclature and subclassification of steatotic liver disease and loss of skeletal muscle mass: A longitudinal cohort study Aryoung Kim, Danbee Kang, Sung Chul Choi, Dong Hyun Sinn, Geum‐Youn Gwak Hepatology Research.2025; 55(3): 373. CrossRef
Sarcopenia is associated with new-onset acute biliary infection within 1 year in patients with hepatitis B virus-related decompensated cirrhosis Shuangshuang Zhang, Tian Zhou, Mingbo Wu, Xuanxuan Xiong European Journal of Gastroenterology & Hepatology.2025; 37(1): 100. CrossRef
Changes in serum myostatin levels among patients with type C liver cirrhosis treated with direct‐acting antivirals Tomoyuki Suehiro, Hideko Kozuru, Kosuke Matusmoto, Yuki Kugiyama, Yasuhide Motoyoshi, Akira Saeki, Shinya Nagaoka, Kazumi Yamasaki, Atsumasa Komori, Hiroshi Yatsuhashi Hepatology Research.2025; 55(5): 631. CrossRef
Correlation of sarcopenia with progression of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease: a study from two cohorts in China and the United States Fan Zhang, Longgen Liu, Wenjian Li Nutrition Journal.2025;[Epub] CrossRef
Cirrhosis Promotes Cardiac Fibrosis Development by Inhibiting Notch1 in Cardiac Fibroblasts He Sun, Kai Song, Ze-Yu Zhou, Bin Tu, Yang Zhou, Li-Chan Lin, Zhi-Yan Liu, Zhen-Yu Liu, Ji-Ming Sha, Yan Shi, Jing-Jing Yang, Dong Lu, Jian-Yuan Zhao, Hui Tao JACC: Basic to Translational Science.2025; 10(5): 612. CrossRef
Rifaximin-α use is associated with improved muscle mass in patients with cirrhosis Thomas Worland, Penelope Hey, Darren Wong, Ross Apostolov, Roseanne Kimberley Chan, Marie Sinclair, Paul Gow World Journal of Hepatology.2025;[Epub] CrossRef
Association of sarcopenia and physical activity on the severity of metabolic dysfunction-associated steatotic liver disease among United States adults: NHANES 2017 - 2018 Xiaodie Wei, Xiaohui Liu, Jinhan Zhao, Yang Zhang, Lixia Qiu, Jing Zhang Frontiers in Aging.2025;[Epub] CrossRef
Steatotic liver disease is a marker of multimorbidity, not underlying cirrhosis, in older adults O. Oduwole, C. Ding, N. Bitar, D. Nair, S. Salter, M. Silverman, R. Allen, L. Ng Fat, E. Tsochatzis, S. Bell, G. Mehta, A. Britton npj Gut and Liver.2025;[Epub] CrossRef
Peripheral blood inflammatory score using a cytokine multiplex assay predicts clinical outcomes in patients treated with atezolizumab-bevacizumab for unresectable HCC Hee Sun Cho, Soon Kyu Lee, Ji Won Han, Jung Hyun Kwon, Soon Woo Nam, Jaejun Lee, Keungmo Yang, Pil Soo Sung, Jeong Won Jang, Seung Kew Yoon, Jong Young Choi Frontiers in Immunology.2025;[Epub] CrossRef
Rifaximin and sarcopenia in cirrhosis: Commentary on a promising but complex relationship Mohamed El-Kassas, Khalid AlNaamani World Journal of Hepatology.2025;[Epub] CrossRef
Impact of low preoperative appendicular skeletal muscle mass on postoperative complications and short-term outcomes in liver transplant recipients: a propensity score-matched retrospective study Jing Xu, Qian Wu, Xiaofeng Xu, Feihong Weng, Tao Lv, Jian Yang, Shouping Wang, Rui Li, Chengbo Ai, Gang Xu, Lvnan Yan, Jiayin Yang Frontiers in Surgery.2025;[Epub] CrossRef
Nutritional screening and assessment tools for patients with cirrhosis based on the Global Leadership Initiative on Malnutrition criteria Yumei He, Ling Hu, Shiyan Wu, Lu Li, Ke Zhong, Jiazhen Li, Na Liu, Xiaobin Sun, Qiong Wang, Chao Sun, Liping Wu Journal of Human Nutrition and Dietetics.2024; 37(2): 430. CrossRef
Screening and assessment of malnutrition in patients with liver cirrhosis Yumei He, Zhiming Wang, Shiyan Wu, Lu Li, Jiazhen Li, Yexing Zhang, Boshi Chen, Xiaobin Sun, Chao Sun, Liping Wu Frontiers in Nutrition.2024;[Epub] CrossRef
Bibliometrics and knowledge mapping of the pathogenesis of hepatic encephalopathy in patients with liver cirrhosis Shiyan Wu, Lu Li, Heng Xi, Xiaoping Wu, Yumei He, Xiaobin Sun, Liping Wu Heliyon.2024; 10(15): e34330. CrossRef
Unraveling the mechanisms of hepatogenous diabetes and its therapeutic perspectives Manisha Yadav, Smriti Verma, Purnima Tiwari, Madhav Nilakanth Mugale Life Sciences.2024; 353: 122934. CrossRef
The Interplay Between Depression, Probiotics, Diet, Immunometabolic Health, the Gut, and the Liver—A Secondary Analysis of the Pro-Demet Randomized Clinical Trial Oliwia Gawlik-Kotelnicka, Jakub Rogalski, Karolina H. Czarnecka-Chrebelska, Jacek Burzyński, Paulina Jakubowska, Anna Skowrońska, Dominik Strzelecki Nutrients.2024; 16(23): 4024. CrossRef
Effects of Alnus japonica Hot Water Extract and Oregonin on Muscle Loss and Muscle Atrophy in C2C12 Murine Skeletal Muscle Cells Da Hyeon An, Chan Ho Lee, Yeeun Kwon, Tae Hee Kim, Eun Ji Kim, Jae In Jung, Sangil Min, Eun Ju Cheong, Sohyun Kim, Hee Kyu Kim, Sun Eun Choi Pharmaceuticals.2024; 17(12): 1661. CrossRef
Letter regarding “Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis” Do Seon Song, U Im Chang, Jin Mo Yang Clinical and Molecular Hepatology.2023; 29(1): 165. CrossRef
Interaction between sarcopenia and nonalcoholic fatty liver disease Sae Kyung Joo, Won Kim Clinical and Molecular Hepatology.2023; 29(Suppl): S68. CrossRef
Sarcopenia in cirrhosis: epidemiology, diagnosis, management and prognosis Yi Liu, Fanpu Ji, Mindie H. Nguyen Current Opinion in Gastroenterology.2023; 39(3): 131. CrossRef
RETRACTED: Sinapic Acid Attenuate Liver Injury by Modulating Antioxidant Activity and Inflammatory Cytokines in Thioacetamide-Induced Liver Cirrhosis in Rats Ahmed Jabbar, Zaenah Alamri, Mahmood Abdulla, Ahmed AlRashdi, Soran Najmaldin, Mustafa Zainel Biomedicines.2023; 11(5): 1447. CrossRef
The Accuracy of Ultrasound Controlled Attenuation Parameter in Diagnosing Hepatic Fat Content Sebastiana Atzori, Yasmin Pasha, James B Maurice, Simon D Taylor-Robinson, Louise Campbell, Adrian KP Lim Hepatic Medicine: Evidence and Research.2023; Volume 15: 51. CrossRef
Sarcopenia in cirrhosis: Prospects for therapy targeted to gut microbiota Roman Maslennikov, Aliya Alieva, Elena Poluektova, Yury Zharikov, Andrey Suslov, Yana Letyagina, Ekaterina Vasileva, Anna Levshina, Evgenii Kozlov, Vladimir Ivashkin World Journal of Gastroenterology.2023; 29(27): 4236. CrossRef
Skeletal muscle fibre morphology in childhood—insights into myopenia in pediatric liver disease Amber Hager, Vera Mazurak, Michelle Noga, Susan M. Gilmour, Diana R. Mager Applied Physiology, Nutrition, and Metabolism.2023; 48(10): 730. CrossRef
What Does Sarcopenia Have to Do with Nonalcoholic Fatty Liver Disease? Katarzyna Ferenc, Sara Jarmakiewicz-Czaja, Rafał Filip Life.2023; 14(1): 37. CrossRef
Hematological and biochemical investigations on the effect of curcumin and Thymoquinone in male mice exposed to Thioacetamide Atef M. Al-Attar Saudi Journal of Biological Sciences.2022; 29(1): 660. CrossRef
A Review of Sarcopenia Pathophysiology, Diagnosis, Treatment and Future Direction Myung-Rae Cho, Sungho Lee, Suk-Kyoon Song Journal of Korean Medical Science.2022;[Epub] CrossRef
Leaky gut-derived tumor necrosis factor-α causes sarcopenia in patients with liver cirrhosis Takumi Kawaguchi, Takuji Torimura Clinical and Molecular Hepatology.2022; 28(2): 177. CrossRef
Hyun Yang, Hyun Young Woo, Soon Kyu Lee, Ji Won Han, Bohyun Jang, Hee Chul Nam, Hae Lim Lee, Sung Won Lee, Do Seon Song, Myeong Jun Song, Jung Suk Oh, Ho Jong Chun, Jeong Won Jang, Angelo Lozada, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon
Clin Mol Hepatol 2017;23(2):128-137. Published online May 10, 2017
Background/Aims Metronomic chemotherapy (MET) is frequently administered in comparatively low doses as a continuous chemotherapeutic agent. The aim of this study was to evaluate the feasibility and overall survival (OS) of MET compared to sorafenib for advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT).
Methods A total of 54 patients with advanced HCC and PVTT who had undergone MET were analyzed between 2005 and 2013. A total of 53 patients who had undergone sorafenib therapy were analyzed as the control group. The primary endpoint of this study was OS.
Results The median number of MET cycles was two (1-15). The OS values for the MET group and sorafenib group were 158 days (132-184) and 117 days (92-142), respectively (P=0.029). The Cox proportional-hazard model showed that a higher risk of death was correlated with higher serum alpha fetoprotein level (≥400 mg/dL, hazard ratio [HR]=1.680, P=0.014) and Child-Pugh class B (HR=1.856, P=0.008).
Conclusions MET was associated with more favorable outcomes in terms of overall survival than was sorafenib in patients with advanced HCC with PVTT, especially in patients with poor liver function. Therefore, MET can be considered as a treatment option in patients with advanced HCC with PVTT and poor liver function.
Citations
Citations to this article as recorded by
Optimal candidates and surrogate endpoints for HAIC versus Sorafenib in hepatocellular carcinoma: an updated systematic review and meta-analysis Tengfei Si, Qing Shao, Wayel Jassem, Yun Ma, Nigel Heaton International Journal of Surgery.2025; 111(1): 1203. CrossRef
The deubiquitinating enzyme ATXN3 promotes hepatocellular carcinoma progression by stabilizing TAZ Yuanhao Peng, Hui Nie, Kuo Kang, Xuanxuan Li, Yongguang Tao, Yangying Zhou Cancer Gene Therapy.2025; 32(1): 136. CrossRef
Efficacy of hepatic arterial infusion chemotherapy and its combination strategies for advanced hepatocellular carcinoma: A network meta-analysis Shun-An Zhou, Qing-Mei Zhou, Lei Wu, Zhi-Hong Chen, Fan Wu, Zhen-Rong Chen, Lian-Qun Xu, Bi-Ling Gan, Hao-Sheng Jin, Ning Shi World Journal of Gastrointestinal Oncology.2024; 16(8): 3672. CrossRef
Efficacy and Safety of Metronomic Capecitabine in Hepatocellular Carcinoma: A Systematic Review and Meta-analysis Nandini Gupta, Neelkant Verma, Bhoomika Patel Journal of Gastrointestinal Cancer.2024; 55(4): 1485. CrossRef
Clinical significance of exosomal noncoding RNAs in hepatocellular carcinoma: a narrative review Jae Sung Yoo, Min Kyu Kang Journal of Yeungnam Medical Science.2024; 42: 4. CrossRef
Hepatic arterial infusion chemotherapy versus sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombus: An updated meta-analysis and systematic review Wei Zhang, Deliang Ouyang, Zhangkan Huang, Xu Che Frontiers in Oncology.2023;[Epub] CrossRef
Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: A narrative review Zi-Wen Tao, Bao-Quan Cheng, Tao Zhou, Yan-Jing Gao Hepatobiliary & Pancreatic Diseases International.2022; 21(2): 134. CrossRef
A novel chemotherapy strategy for advanced hepatocellular carcinoma: a multicenter retrospective study Juxian Sun, Chang Liu, Jie Shi, Nanya Wang, Dafeng Jiang, Feifei Mao, Jingwen Gu, Liping Zhou, Li Shen, Wan Yee Lau, Shuqun Cheng Chinese Medical Journal.2022; 135(19): 2338. CrossRef
Patterns and Outcomes in Hepatocellular Carcinoma Patients with Portal Vein Invasion: A Multicenter Prospective Cohort Study Dong Hyun Sinn, Hye Won Lee, Yong-Han Paik, Do Young Kim, Yoon Jun Kim, Kang Mo Kim, Si Hyun Bae, Ji Hoon Kim, Yeon Seok Seo, Jae Young Jang, Byoung Kuk Jang, Hyung Joon Yim, Hyung Joon Kim, Byung Seok Lee, Bo Hyun Kim, In Hee Kim, Eun-Young Cho, Jung Il Digestive Diseases and Sciences.2021; 66(1): 315. CrossRef
Survival in untreated hepatocellular carcinoma: A national cohort study Young Ae Kim, Danbee Kang, Hyeyoung Moon, Donghyun Sinn, Minwoong Kang, Sang Myung Woo, Yoon Jung Chang, Boram Park, Sun-Young Kong, Eliseo Guallar, Soo-Yong Shin, Geunyeon Gwak, Joung Hwan Back, Eun Sook Lee, Juhee Cho, Gianfranco D. Alpini PLOS ONE.2021; 16(2): e0246143. CrossRef
Capecitabine Treatment: A Safe and Effective Therapy in the Field of Oncology Linda Beenet Clinical Colorectal Cancer.2021; 20(3): e194. CrossRef
Efficacy and tolerability of Sorafenib plus metronomic chemotherapy S-1 for advanced hepatocellular carcinoma in preclinical and clinical assessments Hiroyuki Suzuki, Hideki Iwamoto, Masahito Nakano, Toru Nakamura, Atsutaka Masuda, Takahiko Sakaue, Toshimitsu Tanaka, Dan Nakano, Ryoko Kuromatsu, Takashi Niizeki, Shusuke Okamura, Shigeo Shimose, Tomotake Shirono, Yu Noda, Naoki Kamachi, Hirohisa Yano, A Translational Oncology.2021; 14(11): 101201. CrossRef
The Role of Hepatic Arterial Infusion Chemotherapy in the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis Shengzhou Li, Jiaxuan Xu, Hongya Zhang, Jiaze Hong, Yuexiu Si, Tong Yang, Yujing He, Derry Minyao Ng, Dingcheng Zheng Chemotherapy.2021; 66(4): 124. CrossRef
Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis Miao Liu, Junyi Shi, Tong Mou, Yang Wang, Zhongjun Wu, Ai Shen Journal of Gastroenterology and Hepatology.2020; 35(8): 1277. CrossRef
Diffusion-Weighted Magnetic Resonance Imaging in Hepatocellular Carcinoma as a Predictor of a Response to Cisplatin-Based Hepatic Arterial Infusion Chemotherapy Pil Soo Sung, Moon Hyung Choi, Hyun Yang, Soon Kyu Lee, Ho Jong Chun, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Joon-Il Choi, Young Joon Lee, Si Hyun Bae Frontiers in Oncology.2020;[Epub] CrossRef
ASPP2 enhances chemotherapeutic sensitivity through the down-regulation of XIAP expression in a p53 independent manner in hepatocellular carcinoma Tongwang Yang, Yuxue Gao, Daojie Liu, Yang Wang, Jing Wu, Xiaoni Liu, Ying Shi, Dexi Chen Biochemical and Biophysical Research Communications.2019; 508(3): 769. CrossRef
Selective embolization with magnetized microbeads using magnetic resonance navigation in a controlled‐flow liver model François Michaud, Ning Li, Rosalie Plantefève, Zeynab Nosrati, Charles Tremblay, Katayoun Saatchi, Gerald Moran, Alexandre Bigot, Urs O. Häfeli, Samuel Kadoury, An Tang, Pierre Perreault, Sylvain Martel, Gilles Soulez Medical Physics.2019; 46(2): 789. CrossRef
Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience Cem Simsek, Ece Esin, Suayib Yalcin Journal of Oncology.2019; 2019: 1. CrossRef
Sorafenib versus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis Bo-wen Zhuang, Wei Li, Xiao-hua Xie, Hang-tong Hu, Ming-de Lu, Xiao-yan Xie Japanese Journal of Clinical Oncology.2019; 49(9): 845. CrossRef
Sorafenib-loaded hydroxyethyl starch-TG100-115 micelles for the treatment of liver cancer based on synergistic treatment Guofei Li, Limei Zhao Drug Delivery.2019; 26(1): 756. CrossRef
Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers Lucia Cerrito, Brigida Eleonora Annicchiarico, Roberto Iezzi, Antonio Gasbarrini, Maurizio Pompili, Francesca Romana Ponziani World Journal of Gastroenterology.2019; 25(31): 4360. CrossRef
Comparison of clinical outcomes between sorafenib and hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma Min Kyu Kang, Jung Gil Park, Heon Ju Lee Medicine.2018; 97(17): e0611. CrossRef
Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis Jong Hwan Choi, Woo Jin Chung, Si Hyun Bae, Do Seon Song, Myeong Jun Song, Young Seok Kim, Hyung Joon Yim, Young Kul Jung, Sang Jun Suh, Jun Yong Park, Do Young Kim, Seung Up Kim, Sung Bum Cho Cancer Chemotherapy and Pharmacology.2018; 82(3): 469. CrossRef
Rationale for the use of metronomic chemotherapy in gastrointestinal cancer Roberto Filippi, Pasquale Lombardi, Ilaria Depetris, Elisabetta Fenocchio, Virginia Quarà, Giovanna Chilà, Massimo Aglietta, Francesco Leone Expert Opinion on Pharmacotherapy.2018; 19(13): 1451. CrossRef
Liver‑targeted delivery of liposome‑encapsulated curcumol using galactosylated‑stearate Wen‑Jie Li, You‑Wen Lian, Quan‑Sheng Guan, Ning Li, Wen‑Jun Liang, Wen‑Xin Liu, Yong‑Bin Huang, Yi Cheng, Hui Luo Experimental and Therapeutic Medicine.2018;[Epub] CrossRef
Can metronomic chemotherapy be an alternative to sorafenib in advanced hepatocellular carcinoma? Do Young Kim Clinical and Molecular Hepatology.2017; 23(2): 123. CrossRef
Background/Aims The treatment strategy for hepatitis C virus (HCV) has been changing rapidly since the introduction of direct-acting antivirals such as daclatasvir (DCV) and asunaprevir (ASV). We evaluated the efficacy and safety of DCV and ASV for HCV in real-life practice.
Methods Patients were treated with 60 mg of DCV once daily plus 200 mg of ASV twice daily for 24 weeks, and followed for 12 weeks. The primary endpoint was a sustained virological response at 12 weeks after treatment (SVR12) and safety.
Results This retrospective study included eight patients with chronic HCV genotype 1b infection. All of the enrolled patients were diagnosed with liver cirrhosis, and their mean age was 65.75 years. One patient was a nonresponder and two patients relapsed with previous pegylated interferon (PegIFN) and ribavirin (RBV) treatment. None of the patient showed NS5A mutation. An SVR12 was achieved in 88% of cases by the DCV and ASV combination therapy. The serum transaminase level and the aspartate-aminotransferase-to-platelet ratio were improved after the treatment. DCV and ASV were well tolerated in most of the patients, with treatment discontinuation due to adverse events (elevated liver enzyme and decompensation) occurring in two patients.
Conclusions In this study, combination of DCV and ASV treatment achieved a high sustained virological response with few adverse events even in those with cirrhosis, advanced age, and nonresponse/relapse to previous interferon-based therapy. Close monitoring of safety issues may be necessary when treating chronic HCV patients receiving DCV and ASV, especially in older patient and those with cirrhosis.
Citations
Citations to this article as recorded by
Clinical outcomes after the introduction of direct antiviral agents for patients infected with genotype 1b hepatitis C virus depending on the regimens: A multicenter study in Korea Jung Hyun Kwon, Sun Hong Yoo, Soon Woo Nam, Hee Yeon Kim, Chang Wook Kim, Chan Ran You, Sang Wook Choi, Se Hyun Cho, Joon‐Yeol Han, Do Seon Song, U Im Chang, Jin Mo Yang, Sung Won Lee, Hae Lim Lee, Nam Ik Han, Seok‐Hwan Kim, Myeong Jun Song, Pil Soo Sung, Journal of Medical Virology.2019; 91(6): 1104. CrossRef
Real‐life effectiveness and safety of the daclatasvir/asunaprevir combination therapy for genotype 1b chronic hepatitis C patients: An emphasis on the pretreatment NS5A resistance‐associated substitution test Eun Sun Jang, Kyung‐Ah Kim, Young Seok Kim, In Hee Kim, Byung Seok Lee, Youn Jae Lee, Woo Jin Chung, Sook‐Hyang Jeong Journal of Medical Virology.2019; 91(12): 2158. CrossRef
An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection Youn Jae Lee, Jeong Heo, Do Young Kim, Woo Jin Chung, Won Young Tak, Yoon Jun Kim, Seung Woon Paik, Eungeol Sim, Susila Kulasingam, Rohit Talwani, Barbara Haber, Peggy Hwang Clinical and Molecular Hepatology.2019; 25(4): 400. CrossRef
Early development of de novo hepatocellular carcinoma after direct‐acting agent therapy: Comparison with pegylated interferon‐based therapy in chronic hepatitis C patients S. H. Yoo, J. H. Kwon, S. W. Nam, H. Y. Kim, C. W. Kim, C. R. You, S. W. Choi, S. H. Cho, J.‐Y. Han, D. S. Song, U. I. Chang, J. M. Yang, H. L. Lee, S. W. Lee, N. I. Han, S.‐H. Kim, M. J. Song, S. Hwang, P. S. Sung, J. W. Jang, S. H. Bae, J. Y. Choi, S. K Journal of Viral Hepatitis.2018; 25(10): 1189. CrossRef
Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C Isabella Esposito, Sebastián Marciano, Julieta Trinks Expert Opinion on Drug Metabolism & Toxicology.2018; 14(6): 649. CrossRef
Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study Byeong Wook Cho, Seok Bae Kim, Il Han Song, Sae Hwan Lee, Hong Soo Kim, Tae Hee Lee, Young Woo Kang, Seok Hyun Kim, Byung Seok Lee, Hee Bok Chae Clinical and Molecular Hepatology.2017; 23(1): 51. CrossRef
Daclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-Analysis Seyed Moayed Alavian, Mohammad Saeid Rezaee-Zavareh Hepatitis Monthly.2016;[Epub] CrossRef
First
Prev
